Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Layth1990on Apr 12, 2021 6:02pm
323 Views
Post# 32982179

RE:Email from Dan

RE:Email from Dan

This managment is not productive at all but that doean't mean the drug won't be successful. I sold my shares over 2 week period at 5+. I have been holding and adding for over 2 years.

things are messy here it's like they don't know their direction. Why RS for example if not listing , why the timing for lame offering that ruined nuance deal and not to mention the pump before good news and the dump. Investors are tired from fake promisses. Dan said no dilution last year at biohub.

if dan won't move his as* and start excuting with no delays, this company will be doomed. One more delay will cause cash burn. Bye bye phase 3 financing, that is why i left. Trust is broken that is why no price movement anymore. I might get back once they release a date for p3 trials to start and i won't mind paying up to 6 / share.

<< Previous
Bullboard Posts
Next >>